
Oral povorcitinib: 75% facial repigmentation in ~19% vs 3-7%
Notas del episodio
Editor's Pick: Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials (Nature Medicine, 2026)
This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.
Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning systemic therapy for chronic inflammatory skin disease, the rising burden of bullous pemphigoid, and pediatric care alongside treatment resistance in scabies and melanoma. Let's dive in.
This week's papers:
- Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials.. Nature Medicine 2026
- Risk of cancer in psoriasis patients treated with biologic therapy: A BADBIR cohort study.. Journal of the European Academy of Dermatology and Venereology 2026
- Dupilumab in Atopic Dermatitis - Rate of Poor Responders and Potential Risk Factors from the TREATgermany Registry.. Acta Dermato-Venereologica 2026
- End-of-Dose Effect as a Guide for Biologic Optimization in Hidradenitis Suppurativa.. JAMA Dermatology 2026
- Increased incidence and healthcare burden of bullous pemphigoid: A population-based cohort study.. Journal of the European Academy of Dermatology and Venereology 2026
- Dipeptidyl Peptidase-4 Inhibitors and Bullous Pemphigoid: A Danish Nationwide Case-Control Study.. Dermatology 2026
- Clinical Outcomes of Nasal Tip Infantile Hemangiomas: A Retrospective Cohort Study.. Pediatric Dermatology 2026
- Expert Recommendations for Use of Combined Oral Contraceptives in Preadolescent and Young Adolescent Patients With Acne Vulgaris.. Pediatric Dermatology 2026
- Ineffectiveness of permethrin in human scabies treatment: A multicenter study of kdr gene mutations.. Journal of the European Academy of Dermatology and Venereology 2026
- Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials.. Nature Medicine 2026
Todos los episodios de AudioScholar Dermatology Weekly (India)